Nonclinical Pharmacology

An integrated approach to GLP regulatory safety pharmacology and early non-GLP discovery pharmacology testing to help you progress from discovery through ICH. Explore testing specializations for in vitro & in vivo cardiovascular (CV) testing as well as neuroscience (CNS) respiratory and drug abuse liability assessments for your nonclinical studies.

Contact Us

More than 100 studies, completed each year

Globally, harmonized platform across technologies

An integrated, multi-disciplinary approach


Meet ICH Requirements & Lower Safety Endpoint Risks 

You need to meet the regulatory requirements of the ICH core battery studies. But what about your own business risks? With many compounds, it’s possible to clear ICH hurdles only to face a host of safety endpoint issues as you advance from discovery, through early development and into clinical study phases. You need a value-added partner to help identify unsafe compounds earlier than ever before.

Access Endpoints During Toxicology Studies 

By looking at safety pharmacology through a business risk lens, you begin to see the process of safety assessment in an entirely different light. Now you can economically assess your endpoints during your toxicology studies to make better safety predictions, earlier than ever before. With many compounds running into safety issues during the clinical phases, there is a great opportunity to anticipate these data in your nonclinical stage, saving you time and money long-term. By better understanding and reducing the risk of drug attrition of your molecule, you are able to progress forward with more confidence — and with the right molecules. Rethink what’s possible and gain a markedly different approach to your early safety assessment regimen.

Let's Start the Conversation

Contact Us